|Day Low/High||0.67 / 0.69|
|52 Wk Low/High||0.48 / 1.51|
Data to be presented in an oral presentation and two poster presentations
Oral Presentation of Long Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease
Concurrently the Company Completes Private Placement of $10 Million Convertible Notes
Multi-product facility to support the potential manufacturing of both pegunigalsidase alfa and taliglucerase alfa on a commercial scale
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
Positive Results in a Number of Clinically Relevant Parameters Suggest Improved Lung Function with alidornase alfa
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.